• GRI Bio Inc GRI.OQ reported a quarterly adjusted loss of $5.80​​ per share for the quarter ended March 31. The lone analyst forecast for the quarter was for a loss of $4.11 per share.

• Reported revenue was zero​; analysts expected zero.

• GRI Bio Inc's reported EPS for the quarter was a loss of $5.80​.

• The company reported a quarterly loss of $3.05 million.

• GRI Bio Inc shares had fallen by 54.1% this quarter and lost 89.6% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 0.7% in the last three months.​

• In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for GRI Bio Inc is $105.00

This summary was machine generated from LSEG data May 15 at 01:32 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)